<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02590575</url>
  </required_header>
  <id_info>
    <org_study_id>SZ_G_023.14-II-4</org_study_id>
    <nct_id>NCT02590575</nct_id>
  </id_info>
  <brief_title>&quot;Low Flow&quot; CO2 Removal on RRT</brief_title>
  <acronym>Prismalung</acronym>
  <official_title>&quot;Low Flow&quot; CO2 Removal Via a Membrane Gas Exchange Device (Prismalung®) on a Renal Replacement Platform (Prismaflex®) in Hypercapnic, Ventilated Patients Requiring Renal Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Frankfurt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effectiveness of a membrane gas exchange device in
      the venovenous circulation of a continuous renal replacement therapy for the purpose of CO2
      elimination and pH compensation. Thus, the primary endpoint is the modification of the PaCO2
      and/or the ventilator settings (tidal volume VT and plateau pressure Pplat).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol synopsis Study title &quot;Low flow&quot; CO2 removal via a membrane gas exchange device
      (Prismalung®) on a renal replacement platform (Prismaflex®) in hypercapnic, ventilated
      patients requiring renal replacement therapy Brief description Prismalung Study Indication
      Hypercapnic, ventilated, and renal replacement therapy requiring patients Primary study goal
      Changes in the arterial pCO2 value Secondary study goals Changes in the acid-base balance
      Changes of tidal volumes/ventilation pressures Changes in hemodynamics Study design
      Prospective intervention study (pilot study)

      Study population Inclusion criteria:

        1. Necessity of renal replacement therapy

        2. Necessity of ventilation therapy with an expected duration &gt;24 hrs. in mild to moderate
           ARDS according to the &quot;Berlin Definition&quot; (300≥PaO2/FiO2&gt;100mmHg, ventilated acc. to the
           ARDS network strategy with VT 6 ml/kgKG (KG = Körpergewicht, body weight) and PEEP ≥ 5
           cmH2O)Pneumonia, pulmonary vasculitis, COPD, or other pulmonary disorder

        3. PaCO2 ≥ 55 mmHg with plateau ventilation pressure &gt; 25 cmH2O and pH &lt; 7.30

        4. Written consent by patient or legal representative

      Number of patients n = 20 Interventions 1. With ongoing continuous hemofiltration and
      mechanical ventilation additional membrane gas exchange device (Prismalung®) in the renal
      replacement circulation; measurements of the effects on PaCO2 under varying blood and sweep
      gas flows 2. Afterwards, reduction of the tidal volume (VT) / plateau pressure until reaching
      the initial PaCO2value Study drug None Primary endpoint 1. Changes in the PaCO2 / acid-base
      status (BGA) 2. Changes of the VT / plateau pressure in the ventilation (ventilation
      settings) Secondary endpoints Changes in the systemic hemodynamics Vasopressor dosage BGA,
      renal values, lactate PaCO2 before and after gas exchange device Lifetimes of the
      extracorporeal circulation Complications Study site Intensive care units Medizinische Klinik
      4, Uniklinikum Erlangen-Nürnberg Medizinische Klinik 4, Klinikum Nürnberg Süd Klinik für
      Intensivmedizin Universitätsklinikum Hamburg Eppendorf Klinik für Anästhesiologie und
      Intensivmedizin Universitätsklinikum Frankfurt a. M. Timeline Start in October 2015
      Anticipated study duration: 6 months Financing Baxter Gambro Renal GmbH (Ltd)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the PaCO2, acid-base status (BGA)</measure>
    <time_frame>hours to 3 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of the VT / plateau pressure in the ventilation (ventilation settings)</measure>
    <time_frame>hours to 3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in mean arterial pressure (mmHg)</measure>
    <time_frame>hours to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in heart rate (bpm)</measure>
    <time_frame>hours to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in norepinephrin dose (mg/h)</measure>
    <time_frame>hours to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Serum lactate concentration (mmol/l)</measure>
    <time_frame>hours to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial pO2 and pCO2 (mmHg)</measure>
    <time_frame>hours to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial bicarbonate concentration (mmol/l)</measure>
    <time_frame>hours to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard Base Excess (mmol/l)</measure>
    <time_frame>hours to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Serum creatinine (mg/dl)</measure>
    <time_frame>hours to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCO2 before and after gas exchange device (mmHg)</measure>
    <time_frame>hours to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lifetime of extracorporeal circuit in hours (Duration from start to end of RRT)</measure>
    <time_frame>hours to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and kind of adverse events during study period deemed clinically significant by investigator (as documented by paper questionnaire)</measure>
    <time_frame>hours to 3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Renal Replacement Therapy</condition>
  <arm_group>
    <arm_group_label>CO2 removal</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Extracorporeal CO2 removal with the Prismalung(R) gas exchanger on the Prismaflex(R) renal replacement platform</intervention_name>
    <description>With ongoing continuous hemofiltration and mechanical ventilation additional membrane gas exchange device (Prismalung®) in the renal replacement circulation; measurements of the effects on PaCO2 under varying blood and sweep gas flows
Afterwards, reduction of the tidal volume (VT) / plateau pressure until reaching the initial PaCO2value</description>
    <arm_group_label>CO2 removal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Necessity of renal replacement therapy

          2. Necessity of ventilation therapy with an expected duration &gt;24 hrs. in mild to
             moderate ARDS according to the &quot;Berlin Definition&quot; (300≥PaO2/FiO2&gt;100mmHg, ventilated
             acc. to the ARDS network strategy with VT 6 ml/kgKG (KG = Körpergewicht, body weight)
             and PEEP ≥ 5 cmH2O) Pneumonia, pulmonary vasculitis, COPD, or other pulmonary disorder

          3. PaCO2 ≥ 55 mmHg with plateau ventilation pressure &gt; 25 cmH2O and pH &lt; 7.30

          4. Written consent by patient or legal representative

        Exclusion Criteria:

          1. Age &lt; 18 years

          2. Pregnancy

          3. BMI &gt; 40 kg/m2

          4. Decompensated heart failure or acute stroke

          5. Severe ARDS (PaO2/FiO2 &lt; 100 mmHg)

          6. Acute cranio-cerebral injury

          7. Severe liver failure (Child-Pugh score &gt;7)

          8. Heparin-induced thrombopenia (HIT II)

          9. Contraindications to the performance of CVVH (continuous venovenous hemofiltration)

         10. Contraindications to systemic anticoagulation

         11. Lacking possibility of access via a dialysis catheter

         12. Surgeries scheduled within 48 hrs of inclusion in the study

         13. Advanced tumor disorder with life expectancy &lt; 1 month

         14. Moribund patients, decision to forego therapy

         15. Lacking consent

         16. Participation in a different intervention study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan John, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Erlangen-Nuernberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Erlangen-Nuernberg</name>
      <address>
        <city>Nuernberg</city>
        <zip>90473</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2015</study_first_submitted>
  <study_first_submitted_qc>October 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2015</study_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Erlangen-Nürnberg Medical School</investigator_affiliation>
    <investigator_full_name>stefan john</investigator_full_name>
    <investigator_title>Prof. Dr. med. Stefan John</investigator_title>
  </responsible_party>
  <keyword>extracorporeal CO2 removal</keyword>
  <keyword>renal replacement therapy</keyword>
  <keyword>Prismalung</keyword>
  <keyword>ARDS</keyword>
  <keyword>hypercapnia</keyword>
  <keyword>Changes in the arterial pCO2 value</keyword>
  <keyword>ventilated</keyword>
  <keyword>Hypercapnic</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

